Upon joining the trial, you will be randomly assigned to one of two treatment groups. This process is called randomization and ensures fair distribution of participants.

One group will receive BNT327 combined with chemotherapy (etoposide and carboplatin). The other group will receive atezolizumab combined with the same chemotherapy drugs.

Neither you nor your doctor will know which treatment group you are in. This is called a double-blinded trial and helps ensure accurate results.

You will receive treatment through intravenous infusion, which means the medication will be delivered directly into your vein.

The treatment consists of either BNT327 or atezolizumab combined with two chemotherapy drugs: etoposide and either carboplatin or cisplatin.

All medications will be administered as infusions into your vein during scheduled visits to the treatment facility.

This combination treatment phase will continue for a specified number of cycles as determined by the trial protocol.

After completing the initial combination treatment phase, you will continue receiving either BNT327 or atezolizumab alone, without the chemotherapy drugs.

This maintenance treatment will be given through intravenous infusion at regular intervals.

The treatment will continue until your disease progresses, unacceptable side effects occur, or other reasons require stopping the treatment.

Throughout the trial, you will have regular medical examinations and tests to monitor your health and how the treatment is working.

Blood tests will be performed to check your blood cell counts, liver function, and kidney function.

Imaging scans will be conducted at scheduled intervals to assess your tumor size and whether the cancer has progressed.

You will be asked to complete questionnaires about your quality of life, physical functioning, and symptoms such as coughing, shortness of breath, and other lung cancer-related issues.

Any side effects or health changes you experience will be carefully recorded and assessed.

If you are a woman of childbearing potential, you must use a highly effective form of contraception starting from your first visit and continuing until 6 months after your last dose of trial treatment, or 7 months after the last dose of cisplatin if you received it, whichever is later.

If you are a man who is sexually active with a female partner and have not had a vasectomy, you must use condoms and your partner must also use highly effective contraception during the same time period.

You must not donate or store sperm, eggs, or other reproductive cells for assisted reproduction purposes during the trial and for the same time period after your last treatment dose.

After you stop receiving trial treatment, you will continue to be monitored for your overall health and survival.

Information about any subsequent cancer treatments you receive after the trial treatment will be collected.

Your participation in the follow-up phase helps assess the long-term effectiveness of the treatment.